Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Analysis of Gene Expression Following Treatment with BTK and PI3Kδ Inhibitors in Chronic Lymphocytic Leukemia Reveals CXCR4 as a Potential Target for Combination Therapy

  • By

  • Gabriela Mladonicka Pavlasova

  • Veronika Sandova

  • Laura Ondrisova

  • Vaclav Seda

  • Petra Pavelkova

  • Daniel Filip

  • Krystof Hlavac

  • Josef Vecera

  • Sarka Pospisilova

  • Anna Panovska

  • Stacey M. Fernandes

  • Michael Doubek

  • Jennifer R. Brown

  • Marek Mraz

  • September 25, 2026

Share

  • 1

    BTK and PI3Kδ inhibitors are effective in chronic lymphocytic leukemia (CLL), with BTK inhibitors preferred due to lower toxicity.

  • 2

    Treatment with ibrutinib and idelalisib significantly altered gene expression, affecting 225 and 340 mRNAs respectively.

  • 3

    Both inhibitors suppressed CD20 expression, complicating the use of anti-CD20 antibodies in combination therapies.

  • 4

    CXCR4, IL2RA, and ROR1 were upregulated after treatment, indicating potential targets for monoclonal antibody therapies.

  • 5

    The study highlights CXCR4 as a promising target for combination therapy in CLL, given its role in cell migration and poor prognosis.

Original Source(s)

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy

  • by Gabriela Mladonicka Pavlasova, Veronika Sandova, Laura Ondrisova, Vaclav Seda, Petra Pavelkova, Daniel Filip, Krystof Hlavac, Josef Vecera, Sarka Pospisilova, Anna Panovska, Stacey M. Fernandes, Michael Doubek, Jennifer R. Brown, Marek Mraz

  • September 25, 2026

Related Content

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)